Hot Flashes, Vasomotor Symptoms Associated With Menopause
Conditions
Keywords
Menopause
Brief summary
Researchers are looking for a better way to treat women who have hot flashes after they have been through the menopause. Hot flashes are caused by the hormonal changes that happen when a woman's body has been through the menopause. Menopause is when women stop having a menstrual cycle, also called a period. During the menopause, the ovaries increasingly produce less sex hormones as a result of the natural ageing process and related hormonal adjustments. The decline in hormone production can lead to various symptoms which, in some cases, can have a very adverse effect on a menopausal woman's quality of life. The study treatment, elinzanetant, was developed to treat symptoms caused by hormonal changes. It works by blocking a protein called neurokinin from sending signals to other parts of the body, which is thought to play a role in starting hot flashes. There are treatments for hot flashes in women who have been through the menopause, but may cause medical problems for some people. In this study, the researchers will learn how well elinzanetant works compared to a placebo in women who have been through the menopause and have hot flashes. A placebo is a treatment that looks like a medicine but does not have any medicine in it. To compare these study treatments, the participants will record information about their hot flashes in an electronic diary. The researchers will study the number of hot flashes the participants have and how severe they are. They will study the results from before treatment and after 12 weeks of treatment. The participants in this study will take two capsules of either elinzanetant or the placebo once a day. The participants will take the study treatments for 52 weeks. During the study, the participants will visit their study site approximately 11 times and perform 2 visits by phone. Each participant will be in the study for approximately 62 weeks. During the study, the participants will: * record information about their hot flashes in an electronic diary * answer questions about their symptoms The doctors will: * check the participants' health * take blood samples * ask the participants questions about what medicines they are taking and if they are having adverse events An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments.
Interventions
120 mg elinzanetant orally once daily
DRUGPlacebo
Matching placebo orally once daily.
Sponsors
Bayer
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
FEMALE
Age
40 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Postmenopausal, defined as: 1. at least 12 months of spontaneous amenorrhea prior to signing of informed consent, or 2. at least 6 months of spontaneous amenorrhea prior to signing of informed consent with serum follicle-stimulating hormone (FSH) levels \> 40 mIU/mL and a serum estradiol concentration of \< 30 pg/mL, or 3. at least 6 months after hysterectomy at signing of informed consent with serum FSH levels \> 40 mIU/mL and a serum estradiol concentration of \< 30 pg/mL, or 4. surgical bilateral oophorectomy with or without hysterectomy at least 6 weeks prior to signing of informed consent. * Moderate to severe hot flash (HF) associated with the menopause and seeking treatment for this condition. * Participant has completed Hot Flash Daily Diary (HFDD) for at least 11 days during the two weeks preceding baseline visit and is showing eligibility with respect to previous inclusion criterion during this time period.
Exclusion criteria
* Any clinically significant prior or ongoing history of arrhythmias, heart block and QT prolongation either determined through clinical history or on ECG evaluation. * Any active ongoing condition that could cause difficulty in interpreting vasomotor symptoms (VMS) such as: infection that could cause pyrexia, pheochromocytoma, carcinoid syndrome. * Current or history (except complete remission for 5 years or more) of any malignancy (except basal and squamous cell skin tumors). Women receiving adjuvant endocrine therapy (e.g. tamoxifen, aromatase inhibitors, GnRH analogues) cannot be enrolled in this study. * Uncontrolled or treatment-resistant hypertension. Women with mild hypertension can be included in the study if they are medically cleared prior to study participation. * Untreated hyperthyroidism or hypothyroidism. * Treated hyperthyroidism with no abnormal increase of thyroid function laboratory parameters and no relevant clinical signs for \> 6 months before signing of informed consent is acceptable. * Treated hypothyroidism with normal thyroid function test results during screening and a stable (for ≥ 3 months before signing of informed consent) dose of replacement therapy is acceptable. * Any unexplained post-menopausal uterine bleeding * Clinically relevant abnormal findings on mammogram. * Abnormal liver parameters. * Disordered proliferative endometrium, endometrial hyperplasia, polyp, or endometrial cancer diagnosed based on endometrial biopsy during screening.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Mean Change in Frequency of Moderate to Severe Hot Flashes (HFs) From Baseline to Week 12 (Assessed by Hot Flash Daily Diary [HFDD]) | Baseline to Week 12 | The HFDD items assess the number of mild, moderate, and severe HF experienced during the day and during the night. Mild HF are defined as a sensation of heat without sweating, moderate HF are defined as a sensation of heat with sweating, but able to continue activity, and severe HF are defined as a sensation of heat with sweating, causing cessation (stopping) of activity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline Over Time. | Baseline to Week 56 | The PROMIS SD SF 8b includes 8 items assessing sleep disturbance over the past 7 days. Items assess sleep quality, sleep depth and restoration associated with sleep, perceived difficulties with getting to sleep or staying asleep and perceptions of the adequacy of and satisfaction with sleep. Participants respond to the items on a 5-point scale from not at all, never or very poor to very much, always or very good. Four of the items are scored reversely. Individual item scores are aggregated to total raw scores which range from 8 to 40. Total raw scores are converted into T-scores for comparison with population norms, with a mean of 50 and standard deviation of 10. T-scores range from 28.9 to 76.5. For both raw and T-scores higher scores indicate greater severity of sleep disturbance. According to available score cut points from PROMIS developers, T-scores can be interpreted as indicating mild (55-59), moderate (60-69), or severe (\>70) sleep disturbance. |
| Mean Change in Menopause Specific Quality of Life Scale (MENQOL) Total Score From Baseline Over Time | Baseline to Week 56 | The MENQOL questionnaire is comprised of 29 items assessing the presence of menopausal symptoms and the impact of menopause on health-related quality of life over the past week. The items assess four domains of symptoms and functioning: Vasomotor functioning, psychosocial functioning, physical functioning, and sexual functioning. For each item, the participant indicates if they have experienced the symptom (yes/no). If they select yes, they rate how bothered they were by the symptom using a six-point verbal descriptor scale, with response options ranging from 0 'not at all bothered' to 6 'extremely bothered'. Based on the individual responses, item scores, domain scores, and a total MENQOL score are calculated. Each score ranges from 1-8, higher scores indicate greater bother. |
Countries
Belgium, Bulgaria, Canada, Denmark, Finland, Poland, Spain, United Kingdom, United States
Participant flow
Recruitment details
The study was conducted at 75 study centers in North America and in several countries in Europe, between 27-Aug-2021 (first participant first visit) and 12-Feb-2024 (last participant last visit).
Pre-assignment details
A total of 1524 patients were screened, of whom 628 were randomized.
Participants by arm
| Arm | Count |
|---|---|
| Elinzanetant (BAY3427080) Participants received 120 mg elinzanetant orally once daily. | 313 |
| Placebo Participants received matching placebo orally once daily. | 315 |
| Total | 628 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 17 | 2 |
| Overall Study | Completed post-treatment/FU visits | 41 | 31 |
| Overall Study | Lack of Efficacy | 0 | 6 |
| Overall Study | Lost to Follow-up | 5 | 2 |
| Overall Study | Non-Compliance with Study Drug | 2 | 3 |
| Overall Study | Other reason | 4 | 3 |
| Overall Study | Physician Decision | 1 | 4 |
| Overall Study | Protocol Violation | 0 | 2 |
| Overall Study | Randomized by Mistake | 0 | 2 |
| Overall Study | Technical Problems | 0 | 1 |
| Overall Study | Withdrawal by Subject | 21 | 28 |
Baseline characteristics
| Characteristic | Placebo | Total | Elinzanetant (BAY3427080) |
|---|---|---|---|
| Age, Continuous | 54.9 Years STANDARD_DEVIATION 5 | 54.7 Years STANDARD_DEVIATION 4.8 | 54.6 Years STANDARD_DEVIATION 4.7 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 34 Participants | 68 Participants | 34 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 273 Participants | 539 Participants | 266 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 8 Participants | 21 Participants | 13 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 2 Participants | 4 Participants | 2 Participants |
| Race (NIH/OMB) Black or African American | 44 Participants | 95 Participants | 51 Participants |
| Race (NIH/OMB) More than one race | 1 Participants | 1 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 1 Participants | 1 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 15 Participants | 34 Participants | 19 Participants |
| Race (NIH/OMB) White | 253 Participants | 493 Participants | 240 Participants |
| Sex: Female, Male Female | 315 Participants | 628 Participants | 313 Participants |
| Sex: Female, Male Male | 0 Participants | 0 Participants | 0 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 313 | 0 / 314 |
| other Total, other adverse events | 85 / 313 | 73 / 314 |
| serious Total, serious adverse events | 13 / 313 | 6 / 314 |
Outcome results
Primary
Mean Change in Frequency of Moderate to Severe Hot Flashes (HFs) From Baseline to Week 12 (Assessed by Hot Flash Daily Diary [HFDD])
The HFDD items assess the number of mild, moderate, and severe HF experienced during the day and during the night. Mild HF are defined as a sensation of heat without sweating, moderate HF are defined as a sensation of heat with sweating, but able to continue activity, and severe HF are defined as a sensation of heat with sweating, causing cessation (stopping) of activity.
Time frame: Baseline to Week 12
Population: All randomized participants with data available at the time of evaluation.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Elinzanetant (BAY3427080) | Mean Change in Frequency of Moderate to Severe Hot Flashes (HFs) From Baseline to Week 12 (Assessed by Hot Flash Daily Diary [HFDD]) | Change from Baseline | -5.40 Number of HF | Standard Deviation 7.29 |
| Elinzanetant (BAY3427080) | Mean Change in Frequency of Moderate to Severe Hot Flashes (HFs) From Baseline to Week 12 (Assessed by Hot Flash Daily Diary [HFDD]) | Baseline | 6.71 Number of HF | Standard Deviation 7.15 |
| Placebo | Mean Change in Frequency of Moderate to Severe Hot Flashes (HFs) From Baseline to Week 12 (Assessed by Hot Flash Daily Diary [HFDD]) | Baseline | 6.81 Number of HF | Standard Deviation 6.15 |
| Placebo | Mean Change in Frequency of Moderate to Severe Hot Flashes (HFs) From Baseline to Week 12 (Assessed by Hot Flash Daily Diary [HFDD]) | Change from Baseline | -3.50 Number of HF | Standard Deviation 4.96 |
Comparison: For category Change from baseline.p-value: <0.000195% CI: [-2.04, -1.05]Mixed model repeated measures (MMRM)
Secondary
Mean Change in Menopause Specific Quality of Life Scale (MENQOL) Total Score From Baseline Over Time
The MENQOL questionnaire is comprised of 29 items assessing the presence of menopausal symptoms and the impact of menopause on health-related quality of life over the past week. The items assess four domains of symptoms and functioning: Vasomotor functioning, psychosocial functioning, physical functioning, and sexual functioning. For each item, the participant indicates if they have experienced the symptom (yes/no). If they select yes, they rate how bothered they were by the symptom using a six-point verbal descriptor scale, with response options ranging from 0 'not at all bothered' to 6 'extremely bothered'. Based on the individual responses, item scores, domain scores, and a total MENQOL score are calculated. Each score ranges from 1-8, higher scores indicate greater bother.
Time frame: Baseline to Week 56
Population: All randomized participants with data available at the time of evaluation.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Elinzanetant (BAY3427080) | Mean Change in Menopause Specific Quality of Life Scale (MENQOL) Total Score From Baseline Over Time | Change from baseline to Week 8 | -1.07 Scores on a scale | Standard Deviation 1.24 |
| Elinzanetant (BAY3427080) | Mean Change in Menopause Specific Quality of Life Scale (MENQOL) Total Score From Baseline Over Time | Change from baseline to Week 12 | -1.10 Scores on a scale | Standard Deviation 1.25 |
| Elinzanetant (BAY3427080) | Mean Change in Menopause Specific Quality of Life Scale (MENQOL) Total Score From Baseline Over Time | Change from baseline to Week 52 | -1.30 Scores on a scale | Standard Deviation 1.33 |
| Elinzanetant (BAY3427080) | Mean Change in Menopause Specific Quality of Life Scale (MENQOL) Total Score From Baseline Over Time | Baseline | 4.10 Scores on a scale | Standard Deviation 1.21 |
| Elinzanetant (BAY3427080) | Mean Change in Menopause Specific Quality of Life Scale (MENQOL) Total Score From Baseline Over Time | Change from baseline to Week 4 | -0.94 Scores on a scale | Standard Deviation 1.22 |
| Elinzanetant (BAY3427080) | Mean Change in Menopause Specific Quality of Life Scale (MENQOL) Total Score From Baseline Over Time | Change from baseline to Week 18 | -1.30 Scores on a scale | Standard Deviation 1.32 |
| Elinzanetant (BAY3427080) | Mean Change in Menopause Specific Quality of Life Scale (MENQOL) Total Score From Baseline Over Time | Change from baseline to Week 24 | -1.25 Scores on a scale | Standard Deviation 1.17 |
| Elinzanetant (BAY3427080) | Mean Change in Menopause Specific Quality of Life Scale (MENQOL) Total Score From Baseline Over Time | Change from baseline to Week 36 | -1.18 Scores on a scale | Standard Deviation 1.21 |
| Elinzanetant (BAY3427080) | Mean Change in Menopause Specific Quality of Life Scale (MENQOL) Total Score From Baseline Over Time | Change from baseline to Week 56 (Follow-up) | -0.82 Scores on a scale | Standard Deviation 1.25 |
| Placebo | Mean Change in Menopause Specific Quality of Life Scale (MENQOL) Total Score From Baseline Over Time | Change from baseline to Week 36 | -1.02 Scores on a scale | Standard Deviation 1.42 |
| Placebo | Mean Change in Menopause Specific Quality of Life Scale (MENQOL) Total Score From Baseline Over Time | Change from baseline to Week 8 | -0.86 Scores on a scale | Standard Deviation 1.18 |
| Placebo | Mean Change in Menopause Specific Quality of Life Scale (MENQOL) Total Score From Baseline Over Time | Change from baseline to Week 18 | -1.11 Scores on a scale | Standard Deviation 1.4 |
| Placebo | Mean Change in Menopause Specific Quality of Life Scale (MENQOL) Total Score From Baseline Over Time | Change from baseline to Week 52 | -1.11 Scores on a scale | Standard Deviation 1.35 |
| Placebo | Mean Change in Menopause Specific Quality of Life Scale (MENQOL) Total Score From Baseline Over Time | Change from baseline to Week 24 | -1.15 Scores on a scale | Standard Deviation 1.37 |
| Placebo | Mean Change in Menopause Specific Quality of Life Scale (MENQOL) Total Score From Baseline Over Time | Baseline | 4.41 Scores on a scale | Standard Deviation 1.37 |
| Placebo | Mean Change in Menopause Specific Quality of Life Scale (MENQOL) Total Score From Baseline Over Time | Change from baseline to Week 56 (Follow-up) | -1.04 Scores on a scale | Standard Deviation 1.59 |
| Placebo | Mean Change in Menopause Specific Quality of Life Scale (MENQOL) Total Score From Baseline Over Time | Change from baseline to Week 4 | -0.67 Scores on a scale | Standard Deviation 1.21 |
| Placebo | Mean Change in Menopause Specific Quality of Life Scale (MENQOL) Total Score From Baseline Over Time | Change from baseline to Week 12 | -0.95 Scores on a scale | Standard Deviation 1.32 |
Secondary
Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline Over Time.
The PROMIS SD SF 8b includes 8 items assessing sleep disturbance over the past 7 days. Items assess sleep quality, sleep depth and restoration associated with sleep, perceived difficulties with getting to sleep or staying asleep and perceptions of the adequacy of and satisfaction with sleep. Participants respond to the items on a 5-point scale from not at all, never or very poor to very much, always or very good. Four of the items are scored reversely. Individual item scores are aggregated to total raw scores which range from 8 to 40. Total raw scores are converted into T-scores for comparison with population norms, with a mean of 50 and standard deviation of 10. T-scores range from 28.9 to 76.5. For both raw and T-scores higher scores indicate greater severity of sleep disturbance. According to available score cut points from PROMIS developers, T-scores can be interpreted as indicating mild (55-59), moderate (60-69), or severe (\>70) sleep disturbance.
Time frame: Baseline to Week 56
Population: All randomized participants with data available at the time of evaluation.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Elinzanetant (BAY3427080) | Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline Over Time. | Change from baseline to Week 2 | -6.78 T-score | Standard Deviation 7.96 |
| Elinzanetant (BAY3427080) | Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline Over Time. | Baseline | 57.35 T-score | Standard Deviation 6.66 |
| Elinzanetant (BAY3427080) | Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline Over Time. | Change from baseline to Week 1 | -5.19 T-score | Standard Deviation 7.17 |
| Elinzanetant (BAY3427080) | Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline Over Time. | Change from baseline to Week 3 | -7.67 T-score | Standard Deviation 8.24 |
| Elinzanetant (BAY3427080) | Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline Over Time. | Change from baseline to Week 4 | -7.70 T-score | Standard Deviation 8.27 |
| Elinzanetant (BAY3427080) | Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline Over Time. | Change from baseline to Week 8 | -7.98 T-score | Standard Deviation 8.58 |
| Elinzanetant (BAY3427080) | Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline Over Time. | Change from baseline to Week 12 | -7.97 T-score | Standard Deviation 8.04 |
| Elinzanetant (BAY3427080) | Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline Over Time. | Change from baseline to Week 18 | -8.83 T-score | Standard Deviation 9.05 |
| Elinzanetant (BAY3427080) | Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline Over Time. | Change from baseline to Week 24 | -9.77 T-score | Standard Deviation 9 |
| Elinzanetant (BAY3427080) | Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline Over Time. | Change from baseline to Week 36 | -9.20 T-score | Standard Deviation 8.74 |
| Elinzanetant (BAY3427080) | Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline Over Time. | Change from baseline to Week 52 | -9.36 T-score | Standard Deviation 8.41 |
| Elinzanetant (BAY3427080) | Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline Over Time. | Change from baseline to Week 56 (Follow-up) | -5.83 T-score | Standard Deviation 8.71 |
| Placebo | Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline Over Time. | Change from baseline to Week 52 | -5.73 T-score | Standard Deviation 7.91 |
| Placebo | Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline Over Time. | Change from baseline to Week 8 | -4.36 T-score | Standard Deviation 7.64 |
| Placebo | Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline Over Time. | Change from baseline to Week 12 | -5.26 T-score | Standard Deviation 8.02 |
| Placebo | Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline Over Time. | Baseline | 57.96 T-score | Standard Deviation 7.63 |
| Placebo | Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline Over Time. | Change from baseline to Week 36 | -5.88 T-score | Standard Deviation 8.38 |
| Placebo | Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline Over Time. | Change from baseline to Week 1 | -1.60 T-score | Standard Deviation 5.39 |
| Placebo | Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline Over Time. | Change from baseline to Week 2 | -2.89 T-score | Standard Deviation 6.78 |
| Placebo | Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline Over Time. | Change from baseline to Week 18 | -5.77 T-score | Standard Deviation 7.82 |
| Placebo | Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline Over Time. | Change from baseline to Week 3 | -3.34 T-score | Standard Deviation 6.88 |
| Placebo | Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline Over Time. | Change from baseline to Week 56 (Follow-up) | -5.38 T-score | Standard Deviation 7.5 |
| Placebo | Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline Over Time. | Change from baseline to Week 4 | -3.81 T-score | Standard Deviation 6.98 |
| Placebo | Mean Change in Patient-reported Outcomes Measurement Information System Sleep Disturbance Short Form 8b (PROMIS SD SF 8b) Total T-score From Baseline Over Time. | Change from baseline to Week 24 | -5.85 T-score | Standard Deviation 7.79 |